

Estimate change	
TP change	
Rating change	

Bloomberg	ASTRA IN
Equity Shares (m)	269
M.Cap.(INRb)/(USDb)	341 / 3.9
52-Week Range (INR)	2040 / 1232
1, 6, 12 Rel. Per (%)	-11/-15/-35
12M Avg Val (INR M)	1010

Financials & Valuations (INR b)

Y/E Mar	2025	2026E	2027E
Sales	58.3	65.5	77.2
EBITDA	9.5	10.6	13.1
PAT	5.2	5.9	8.0
EBITDA (%)	16.2	16.2	17.0
EPS (INR)	19.5	22.1	29.6
EPS Gr. (%)	-4.1	13.6	33.9
BV/Sh. (INR)	180	203	236

Ratios

Net D/E	-0.1	-0.2	-0.3
RoE (%)	15.4	15.5	18.1
RoCE (%)	15.6	15.6	18.0
Payout (%)	19.3	22.6	16.9

Valuations

P/E (x)	65.2	57.4	42.9
EV/EBITDA (x)	35.6	31.4	24.9
Div Yield (%)	0.3	0.4	0.4
FCF Yield (%)	0.2	1.4	2.2

Shareholding Pattern (%)

As on	Jun-25	Mar-25	Jun-24
Promoter	54.1	54.1	54.1
DII	14.9	14.8	12.5
FII	20.1	20.2	22.5
Others	10.9	11.0	11.0

Note: FII includes depository receipts

CMP: INR1,269 TP: INR1,650 (+30%) Buy
Margin contraction due to muted volumes and inventory losses
Earnings below our estimate

- Astral Limited (ASTRA) reported a muted quarter, which was in line with its industry peers due to a volatile pricing scenario and a weak demand environment. ASTRA reported a marginal decline in revenue (down 2% YoY) with flat volume YoY at 56.1k MT. However, its EBITDA margin contracted 190bp YoY to 13.6%, severely impacted by inventory losses and an adverse operating leverage.
- The management commentary on outlook remains in sync with the industry. The company is witnessing a good 2QFY26 to date for its piping and adhesives business (including paints) and remains confident of maintaining its earlier guidance of double-digit revenue growth in FY26. PVC prices are expected to bottom out, and demand improvement will drive the growth and recovery in margins in 9MFY26.
- Factoring in the weak 1Q operating performance and maintenance of management guidance, we cut our FY26E earnings by only 7% (despite a miss of 39% in 1Q). However, we broadly maintain our FY27 estimates. **We reiterate our BUY rating with an SoTP-based TP of INR1,650.**

Weak operating performance across businesses

- ASTRA's consolidated revenue declined 2% YoY/19% QoQ to INR13.6b in 1QFY26 (est. INR15.2b), primarily led by a dip in the plumbing business (down 6% YoY), which was partially offset by a 10% YoY growth in the paints and adhesive business.
- Consolidated EBITDA declined 14% YoY/39% QoQ to INR1.8b (est. INR2.4b), with EBITDA margin contracting 190bp YoY/440bp QoQ to 13.6% (est. 15.5%). This was driven by an increase in employee expenses/raw material as a % of sales by +130bp/+120bp YoY. Adj. PAT declined 33% YoY and 55% QoQ to INR811m (est. INR1.3b).
- The plumbing business reported a volume of 56.1k MT (flat YoY) with revenue at INR9.5b (-6% YoY), largely due to lower realization (down 6% to INR170/kg). EBITDA stood at INR1.6b (-14% YoY), resulting in an EBITDA margin of 16.4% (-150bp YoY). EBITDA/EBIT per kg stood at INR27.9/INR17.6 (down 14%/36% YoY, respectively).
- The paints and adhesive business revenue stood at INR4.1b (up 10% YoY), EBITDA was INR375m (down 16% YoY), and EBITDA margin came in at 9.2% (-280bp YoY). EBIT stood at INR196m (down 25%), with margin at 4.8% (down 220bp YoY).

Highlights from the management commentary

- Outlook:** ASTRA's 1QFY26 volumes were flat due to weak demand, early monsoon, and low government spending, alongside an inventory loss of INR350m. From Jul'25 onwards, volumes have started improving (up 30% YoY), and the company expects "lower double-digit" volume growth for FY26, with potential upside if ADD/BIS spur channel restocking. Piping business EBITDA margins are guided at 16–18%.
- Backward integration:** Astral is acquiring 80% of Nexelon Chem to set up an INR1.5b, 40,000MT CPVC resin plant (commissioning in 2QFY27) using an in-house developed technology. This will be the lowest-cost capacity in the industry, fully for captive use, and is likely to boost margins (in the 25-30% range for CPVC pipes), free working capital, and drive market share as CPVC demand improves.
- Adhesive and paints:** The company delivered decent performance in 1QFY26; however, it maintains a healthy revenue growth guidance for both India adhesives (~15-16% growth and 14-16% margins in FY26) and paints (INR2.4b revenue at 20% growth). Appointed a senior person in the UK Adhesive business and expect a healthy turnaround.

Valuation and view


- Macro headwinds have hit the industry, including ASTRA, over the last few quarters; however, with PVC prices expected to stabilize around this level and demand likely to improve, we anticipate the growth momentum to pick up going forward.
- With new acquisitions and investments in CPVC, the company can further expand its margins profile (which is already the best in the industry) and improve its working capital.
- We expect ASTRA to clock a 15%/17%/22% CAGR in revenue/EBITDA/PAT over FY25-28. **We reiterate our BUY rating on the stock with an SoTP-based TP of INR1,650 (premised on 56x FY27 P/E).**

Consolidated - Quarterly Earnings Model

Y/E March	FY25								FY26E			FY25	FY26E	FY26E	Var %
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q				
Gross Sales	13,836	13,704	13,970	16,814	13,612	15,964	16,198	19,724	58,324	65,497	15,264				-11
YoY Change (%)	7.8	0.5	2.0	3.5	-1.6	16.5	15.9	17.3	3.4	12.3	10.3				
Total Expenditure	11,692	11,603	11,775	13,795	11,763	13,426	13,564	16,128	48,865	54,881	12,895				
EBITDA	2,144	2,101	2,195	3,019	1,849	2,538	2,633	3,596	9,459	10,616	2,369				-22
Margins (%)	15.5	15.3	15.7	18.0	13.6	15.9	16.3	18.2	16.2	16.2	15.5				
Depreciation	556	599	631	648	719	725	739	780	2,434	2,963	670				
Interest	76	102	139	96	123	90	74	50	413	337	88				
Other Income	119	88	118	88	91	140	170	186	413	587	145				
PBT before EO expense	1,631	1,488	1,543	2,363	1,098	1,863	1,990	2,952	7,025	7,903	1,756				
Extra-Ord expense	0	0	0	163	0	0	62	183	0	0	0				
PBT	1,631	1,488	1,543	2,200	1,098	1,863	1,928	2,769	7,025	7,903	1,756				
Tax	436	401	416	583	306	469	502	740	1,836	2,017	443				
Rate (%)	26.7	26.9	27.0	26.5	27.9	25.2	26.0	26.7	26.1	25.5	25.2				
MI & Profit/Loss of Asso. Cos.	-9	-13	-14	-13	-19	-14	-15	-15	0	3	-12				
Reported PAT	1,204	1,100	1,141	1,630	811	1,408	1,442	2,044	5,189	5,883	1,326				
Adj PAT	1,204	1,100	1,141	1,793	811	1,408	1,504	2,227	5,189	5,883	1,326				-39
YoY Change (%)	0.5	-16.2	0.5	-1.3	-32.6	28.0	31.8	24.2	-5.2	13	10				
Margins (%)	8.7	8.0	8.2	10.7	6.0	8.8	9.3	11.3	8.9	9.0	8.7				


Key Exhibits

Exhibit 1: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 2: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 3: Consolidated Adj. PAT trend




Source: Company, MOFSL

Exhibit 4: Revenue mix %



Source: Company, MOFSL

Exhibit 5: EBITDA mix %



Source: Company, MOFSL

Exhibit 6: Plumbing revenue trend




Exhibit 7: Plumbing volume trend




Exhibit 8: Plumbing EBITDA trend




Exhibit 9: Plumbing realization/kg trend




Exhibit 10: Plumbing EBITDA/kg trend




Exhibit 11: Plumbing EBIT/kg trend




Exhibit 12: Paints and Adhesive revenue trend





Exhibit 13: Paints and Adhesive EBITDA trend



Source: Company, MOFSL

Source: Company, MOFSL



Highlights from the management commentary

Guidance and outlook

- Volume was flat in 1QFY26 due to slow demand, early monsoon, and low government spending. Also, inventory loss was ~INR350m in 1QFY26
- However, volume picking up July onwards, and the company is confident of delivering **“lower double-digit” volume growth for FY26, with potential for higher growth if ADD/BIS triggers channel restocking. EBITDA margin will be ~16-18% in the piping business.**
- The piping division has achieved a volume growth of 30% YoY in Jul’25, and in August, it is also doing well. Even the Adhesive division of India has delivered similar growth of 30% plus in value terms on a YoY basis.
- The company has not compromised margins for the volume growth witnessed in July. The company would not shy away from sacrificing 1-2% on margins if it is seeing strong revenue growth to compensate for it.
- 1Q generally has a higher mix of PVC; hence, QoQ realization tends to be lower.
- The pan-India demand has not opened up. Certain pockets are doing better, and certain are improving. From Sep’25, the company is expecting the market to open, as Festivals are early this time. People will spend on home improvements
- ADD is expected to be announced in this quarter, and management is expecting an uptick in PVC prices as they have bottomed out. PVC prices are at a similar level vs. 1QFY26.

Adhesives and Paints

- India Adhesive business is performing well with 9% YoY revenue growth at INR2.61b vs INR2.39b in 1QFY25
- **The segment is on track with a guidance of 15-16% revenue growth for FY26, with margins to be in the range of 14-16%**
- UK Adhesive did INR960m revenue vs INR890m in 1QFY25 i.e. 7% YoY growth and ~5.4% EBITDA margin
- Historically, the UK market has generated ~8-10% EBITDA margins, and the company expects this to settle in at this rate going ahead.
- The company has appointed a new executive (a highly senior person with over 25 years' experience) to lead the business and is seeing a healthy turnaround.
- Last quarter, the gross margin of the adhesive business was the highest in the last four years
- Paints segment delivered 20% growth this quarter with Revenue of ~INR500m vs INR415m in 1QFY25.
- The company is aiming for similar growth in the coming quarters. It is **expecting ~INR2.4b revenue run rate this year.**

Acquisition of NEXELON

- ASTRA has been doing R&D on the CPVC resin for the past three years and has developed this technology in-house. The company has only spent ~INR40-50m on this by setting up a pilot plant and working on 50- 60 kg batch per day.
- ASTRA has entered into an agreement with NEXELON CHEM, whereby ASTRA will acquire 80% of the Equity of that company at the par value of INR80,000/-.

The tentative cost of the project will be INR1.5b to manufacture 40,000MT of CPVC Resin, and ASTRA has committed to invest approx. INR1.2b (i.e. ~80%).

- The balance 20% stake is of the Technical partner who has worked with ASTRA on this technology. For 20% the partner is bringing his own capital.
- ASTRA's **investment and costing will be the lowest in the CPVC industry**
- This capacity will not be sufficient for backward, but will decide on further expansion post stabilization of this plant
- **The plant will be commissioned by 2QFY27 and will be fully used for captive consumption**
- This investment will not only improve market share but also improve margins for the company. Generally CPVC business does ~25-30% margins
- Currently, ASTRA holds ~3 months of RM inventory as it is mostly imported. With this new capacity, investment in working capital will be freed. Currently, the company is sourcing CPVC from DCW locally and Sekisui Chemical (a Japanese company). For PVC, it does not hold more than 1 to 2 weeks of inventory as it's mostly sourced domestically.
- ASTRA is not dependent on any single PVC supplier for its CPVC manufacturing. The company has tested it for the last three years and has built a diversified source. Not seeing any impact of ADD on RM sourcing. Will procure liquid chlorine, and there are many players in Gujarat where ASTRA can source it.
- The spread between CPVC and PVC has narrowed down thereby leading to an increased shift to CPVC.

Capex

- The company has spent ~INR500m in capex in 1QFY26 and plans to spend a total of INR3-3.5b in FY26.
- ASTRAL is not going to do major capacity expansion in pipes for the next two to three years
- Apart from the above, the company is also spending INR1.2b on the new CPVC resin capacity. This will be spread over a period of 12 months.
- The Kanpur plant will be ready by 3Q and will start in a phased manner. Initially, 25,000MT will be added in Kanpur in Phase 1, and it will add more if needed, but the capex for this will be very low. Will serve Northern markets — UP, Bihar, Eastern NC.

Others

- Higher employee costs are due to the company getting into a new business and hence appointing employees for this. Will continue this run rate going ahead, and as a % of sales, will come down with improving revenue.
- ~70% of the piping channels are now selling Bathware (of any brand). The Company has a good presence in the North, West, and South regions. The company will ramp up the East and for this will hire manpower.
- The bathware business takes years to scale up this business as it requires convincing customers and creating a strong brand. The company first aims to touch INR5b topline in the coming years.

Valuation and view

- Macro headwinds have hit the industry, including ASTRA, over the last few quarters; however, with PVC prices expected to stabilize around this level and demand likely to improve, we anticipate the growth momentum to pick up going forward.
- With new acquisitions and investments in CPVC, the company can further expand its margins profile (which is already the best in the industry) and improve its working capital.
- We expect ASTRA to clock a 15%/17%/22% CAGR in revenue/EBITDA/PAT over FY25-28. **We reiterate our BUY rating on the stock with an SoTP-based TP of INR1,650 (premised on 56x FY27 P/E).**

Exhibit 14: Revisions to our estimates

Earnings change (INRm)	Old			New			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	65,914	77,679	90,033	65,497	77,187	89,469	-1%	-1%	-1%
EBITDA	10,989	13,256	15,399	10,616	13,107	15,245	-3%	-1%	-1%
Adj. PAT	6,402	8,167	9,744	5,950	7,967	9,520	-7%	-2%	-2%

Financials and valuations

Consolidated - Income Statement									
Y/E March	(INRm)								
	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	25,779	31,763	43,940	51,585	56,414	58,324	65,497	77,187	89,469
Change (%)	2.8	23.2	38.3	17.4	9.4	3.4	12.3	17.8	15.9
Total RM Cost	15,957	19,689	29,280	34,347	34,590	35,192	38,755	46,082	53,884
Gross profit	9,822	12,074	14,660	17,238	21,824	23,132	26,742	31,105	35,585
Margin (%)	38.1	38.0	33.4	33.4	38.7	39.7	40.8	40.3	39.8
Employees Cost	1,752	1,910	2,453	3,193	4,384	5,179	5,764	6,175	6,800
Other Expenses	3,641	3,719	4,654	5,946	8,257	8,494	10,362	11,823	13,541
Total Expenditure	21,350	25,318	36,387	43,486	47,231	48,865	54,881	64,080	74,224
% of Sales	82.8	79.7	82.8	84.3	83.7	83.8	83.8	83.0	83.0
EBITDA	4,429	6,445	7,553	8,099	9,183	9,459	10,616	13,107	15,245
Margin (%)	17.2	20.3	17.2	15.7	16.3	16.2	16.2	17.0	17.0
Depreciation	1,079	1,165	1,269	1,781	1,976	2,434	2,963	3,121	3,310
EBIT	3,350	5,280	6,284	6,318	7,207	7,025	7,653	9,986	11,935
Int. and Finance Charges	211	116	129	400	291	413	337	132	132
Other Income	121	251	349	267	421	413	587	691	801
PBT bef. EO Exp.	3,260	5,415	6,504	6,185	7,337	7,025	7,903	10,546	12,605
EO Items	-183	-15	0	-18	0	0	0	0	0
PBT after EO Exp.	3,077	5,400	6,504	6,167	7,337	7,025	7,903	10,546	12,605
Total Tax	565	1,248	1,581	1,557	1,880	1,836	2,017	2,651	3,169
Tax Rate (%)	18.4	23.1	24.3	25.2	25.6	26.1	25.5	25.1	25.1
Minority Interest	33	108	85	44	-4	-49	-63	-73	-84
Reported PAT	2,479	4,044	4,838	4,566	5,461	5,238	5,950	7,967	9,520
Adjusted PAT	2,662	4,059	4,838	4,584	5,461	5,238	5,950	7,967	9,520
Change (%)	31.8	52.5	19.2	-5.3	19.1	-4.1	13.6	33.9	19.5
Margin (%)	10.3	12.8	11.0	8.9	9.7	9.0	9.1	10.3	10.6
Consolidated - Balance Sheet									
Y/E March	(INRm)								
	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	151	201	201	269	269	269	269	269	269
Total Reserves	14,878	18,757	23,165	26,843	31,612	35,901	40,506	47,128	55,302
Net Worth	15,029	18,958	23,366	27,112	31,881	36,170	40,775	47,397	55,571
Minority Interest	168	212	278	2,477	804	757	757	757	757
Total Loans	1,856	397	851	773	964	1,439	439	439	439
Deferred Tax Liabilities	430	401	401	409	460	551	551	551	551
Capital Employed	17,483	19,968	24,896	30,771	34,109	38,917	42,522	49,144	57,318
Gross Block	14,218	15,769	18,866	24,578	29,979	35,831	38,659	41,364	43,505
Less: Accum. Deprn.	4,627	5,792	7,061	8,842	10,818	13,252	16,215	19,336	22,646
Net Fixed Assets	9,591	9,977	11,805	15,736	19,161	22,579	22,444	22,028	20,859
Goodwill on Consolidation	2,553	2,570	2,567	3,125	3,133	3,146	3,146	3,146	3,146
Capital WIP	444	566	1,232	1,261	1,506	1,160	2,132	1,426	1,285
Curr. Assets, Loans&Adv.	10,303	13,615	18,268	23,609	21,179	23,675	27,948	38,114	50,076
Inventory	5,404	4,721	7,334	8,746	9,134	10,111	10,767	12,688	14,707
Account Receivables	2,278	2,767	2,691	3,545	3,758	4,353	4,486	5,287	6,128
Cash and Bank Balance	1,301	4,760	6,418	6,821	6,096	6,083	8,766	15,507	23,872
Loans and Advances	1,320	1,367	1,825	4,497	2,191	3,128	3,930	4,631	5,368
Curr. Liability & Prov.	5,409	6,760	8,976	12,960	10,870	11,643	13,148	15,571	18,048
Account Payables	4,754	5,172	7,484	8,000	8,719	8,589	9,775	11,595	13,440
Other Current Liabilities	589	1,519	1,457	4,903	2,090	2,944	3,275	3,859	4,473
Provisions	66	69	35	57	61	110	98	116	134
Net Current Assets	4,894	6,855	9,292	10,649	10,309	12,032	14,800	22,543	32,028
Appl. of Funds	17,483	19,968	24,896	30,771	34,109	38,917	42,522	49,144	57,318

Financials and valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)									
EPS	9.9	15.1	18.0	17.0	20.3	19.5	22.1	29.6	35.4
Cash EPS	13.9	19.4	22.7	23.7	27.6	38.2	44.4	55.2	63.9
BV/Share	55.9	70.5	86.9	100.8	118.5	180.0	203.0	235.9	276.6
DPS	1.0	1.0	2.3	3.5	3.8	3.8	5.0	5.0	5.0
Payout (%)	13.0	6.7	12.5	20.6	18.5	19.3	22.6	16.9	14.1
Valuation (x)									
P/E	128.3	84.1	70.6	74.5	62.5	65.2	57.4	42.9	35.9
Cash P/E	91.3	65.4	55.9	53.7	45.9	33.3	28.6	23.0	19.9
P/BV	22.7	18.0	14.6	12.6	10.7	7.1	6.3	5.4	4.6
EV/Sales	13.3	10.6	7.6	6.5	6.0	5.8	5.1	4.2	3.6
EV/EBITDA	77.2	52.3	44.5	41.4	36.6	35.6	31.4	24.9	20.9
Dividend Yield (%)	0.1	0.1	0.2	0.3	0.3	0.3	0.4	0.4	0.4
FCF per share	7.1	18.3	6.2	9.1	10.0	3.2	17.5	27.7	33.3
Return Ratios (%)									
RoE	19.1	23.9	22.9	18.2	18.5	15.4	15.5	18.1	18.5
RoCE	17.5	23.5	23.0	18.9	18.7	15.6	15.6	18.0	18.4
RoIC	18.1	26.7	29.8	23.7	21.8	17.8	18.0	23.4	27.8
Working Capital Ratios									
Fixed Asset Turnover (x)	1.8	2.0	2.3	2.1	1.9	1.6	1.7	1.9	2.1
Asset Turnover (x)	1.5	1.6	1.8	1.7	1.7	1.5	1.5	1.6	1.6
Inventory (Days)	77	54	61	62	59	63	60	60	60
Debtor (Days)	32	32	22	25	24	27	25	25	25
Creditor (Days)	67	59	62	57	56	54	54	55	55
Leverage Ratio (x)									
Current Ratio	1.9	2.0	2.0	1.8	1.9	2.0	2.1	2.4	2.8
Interest Cover Ratio	15.9	45.5	48.7	15.8	24.8	17.0	22.7	75.8	90.6
Net Debt/Equity	0.0	-0.2	-0.2	-0.2	-0.2	-0.1	-0.2	-0.3	-0.4

Consolidated - Cash Flow Statement

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	(INRm) FY28E
OP/(Loss) before Tax	3,061	5,330	6,504	6,152	7,336	7,025	7,903	10,546	12,605
Depreciation	1,079	1,165	1,269	1,781	1,976	2,434	2,963	3,121	3,310
Interest & Finance Charges	394	131	-220	400	291	413	-250	-560	-670
Direct Taxes Paid	-815	-1,162	-1,581	-1,654	-1,772	-1,701	-2,017	-2,651	-3,169
(Inc)/Dec in WC	188	1,142	-541	-1,026	500	-1,718	-85	-1,001	-1,119
CF from Operations	3,907	6,606	5,431	5,653	8,331	6,453	8,514	9,454	10,956
Others	147	36	0	-84	-97	-157	0	0	0
CF from Operating incl EO	4,054	6,642	5,431	5,569	8,234	6,296	8,514	9,454	10,956
(Inc)/Dec in FA	-2,133	-1,711	-3,760	-3,110	-5,539	-5,448	-3,800	-2,000	-2,000
Free Cash Flow	1,921	4,931	1,671	2,459	2,695	848	4,714	7,454	8,956
(Pur)/Sale of Investments	18	48	0	0	0	0	0	0	0
Others	-1,062	-2,878	4,475	-1,687	129	322	587	691	801
CF from Investments	-3,177	-4,541	715	-4,797	-5,410	-5,126	-3,213	-1,309	-1,199
Issue of Shares	0	1	0	0	0	0	0	0	0
Inc/(Dec) in Debt	-936	-1,188	454	-384	191	440	-1,000	0	0
Interest Paid	-409	-140	-129	-366	-267	-342	-337	-132	-132
Dividend Paid	-240	-151	-605	-603	-1,007	-1,007	-1,345	-1,345	-1,345
Others	1,117	3,998	-4,208	984	-2,466	-272	63	73	84
CF from Fin. Activity	-468	2,520	-4,488	-369	-3,549	-1,181	-2,618	-1,404	-1,393
Inc/Dec of Cash	409	4,621	1,658	403	-725	-11	2,683	6,742	8,365
Opening Balance	892	139	4,760	6,418	6,821	6,094	6,083	8,766	15,507
Closing Balance	1,301	4,760	6,418	6,821	6,096	6,083	8,766	15,507	23,872

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRCL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalystPublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Rajani

Name: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: No.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company

- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dgrievances@motilaloswal.com.